(Posted By: Josi Creek)
Biogen Idec and Elan Pharmaceuticals have announced the enrolment of the first patient-in-large, well-controlled, head-to-head study of multiple sclerosis (MS) treatments, directly comparing Tysabri to Copaxone (Teva) and Rebif (Merck Serono). The study, called SURPASS, is a global Phase IIIb, randomised, rater-blinded, active-controlled study.
To read the full story, click here.
